Fresenius SE & Co. KGaA
FSNUF
Other OTC54.35
USD
- -
- -
ISIN
DE0005785604
Return %
Stock
S&P500
1Y
44.05
26.53
3Y
75.32
76.60
5Y
7.54
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Michael Sen
- Full Time Employees
- 175,202
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- Else-Kroener-Strasse 1 Bad Homburg vor der Höhe Germany 61352
- IPO Date
- Mar 14, 2012
- Website
- fresenius.com
- Similar Companies
- Business
- Fresenius SE & Co. KGaA stands as a prominent global healthcare enterprise, delivering essential products and comprehensive services across various medical fields. The company’s diverse operations are structured primarily through its key segments: Fresenius Kabi, Fresenius Helios, and its investment in Fresenius Medical Care, alongside ongoing strategic adjustments concerning Fresenius Vamed. The Fresenius Kabi segment focuses on critically and chronically ill patients, providing a wide array of life-sustaining medicines and medical technologies. Its portfolio encompasses intravenously administered generic drugs for areas like oncology and critical care, parenteral and enteral nutrition solutions, infusion therapies, advanced medical devices for drug administration and clinical nutrition, and biosimilar treatments for autoimmune and cancer conditions, in addition to transfusion products for blood component collection and therapeutic apheresis. Fresenius Helios operates as a leading private healthcare service provider throughout Europe. This division includes numerous hospitals and a broad network of outpatient facilities across Germany, Spain, and Latin America, offering a full spectrum of inpatient and outpatient medical and nursing care. The Fresenius Medical Care segment is dedicated to individuals suffering from chronic kidney disease, supplying a comprehensive range of products and services for dialysis. This includes state-of-the-art dialyzers, hemodialysis machines, associated disposable items, and specialized dialysis care services, supporting both in-center and home-based therapies. Fresenius SE & Co. KGaA maintains a significant ownership stake in Fresenius Medical Care, which transitioned to being managed as a financial investment and was deconsolidated in 2023. Regarding Fresenius Vamed, the company has initiated a structured exit from this segment as part of its #FutureFresenius strategy. Vamed's operations previously involved managing projects and providing services for hospitals and other healthcare facilities internationally, encompassing development, planning, turnkey construction, and technical and operational management. Its international project business was fully divested in early 2025, and Austrian operations are in the process of being sold, while Vamed's High-End Services unit, focusing on technical and medical technology management for healthcare facilities, is being integrated into Fresenius as Fresenius Health Services (FHS) starting January 1, 2025. Fresenius SE & Co. KGaA, founded in 1912, is headquartered in Bad Homburg vor der Höhe, Germany.
Fresenius SE & Co. KGaA (FSNUY) Q1 2026 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q2 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q1 2025 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Full Year and Q4 2024 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q3 2024 Earnings Call Transcript
Fresenius SE & Co. KGaA (FSNUF) Q2 2024 Earnings Call Transcript